Dear Dietmar Weixler,
President of the Österreichische Palliativgesellschaft,
I am writing on behalf of our research team currently engaged in the project "EOLinPLACE - Choice of where we die: a classification reform to discern diversity in individual end of life pathways" (https://www.uc.pt/en/eolinplace/) funded by the European Research Council under the European Commission Horizon 2020 Programme. The project endeavours to develop a pioneering international classification tool that maps preferred and actual places towards death.
As part of our ongoing research, we are pleased to announce a recent publication of an umbrella review on Patient and Family Preferences about Place of End-of-Life Care and Death in Journal of Pain and Symptom Management.
Full paper: https://www.jpsmjournal.com/article/S0885-3924(24)00016-2/fulltext
Key findings: HERE (including Infographic and a Plain language summary).
In this study, we collected and analyzed data from 309 studies published in the last 50 years, across 307 countries and on all 5 continents, involving information from over 100,000 patients (adults and children) with various diseases (both oncological and non-oncological), as well as from more than 30,000 family caregivers.
We would greatly appreciate your support in disseminating this publication within your respective organizations and networks.
By sharing this research, we aim to ensure its broader reach and impact in informing discussions and practices related to end-of-life care.
Should you have any questions or require further information, please do not hesitate to reach out to us.
Best regards,
Sara Pinto
Postdoctoral fellow, PhD, MSc, RN
Nursing School of Porto, Cintesis@Rise | sara.o.pinto[at]gmail.com, sarapinto[at]esenf.pt
Published with open access: New findings from an umbrella review show a broad spectrum of preferred places for end-of-life care and death. Home is the preferred place, while some choose hospital or hospice/palliative care facility. Congruence between preferred and actual place is higher since 2004 but lower among non-cancer patients.
